JAMP-ASA 81MG EC TABLET (ENTERIC-COATED)

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ACETYLSALICYLIC ACID

可用日期:

VITA HEALTH PRODUCTS INC

ATC代码:

B01AC06

INN（国际名称）:

ACETYLSALICYLIC ACID

剂量:

81MG

药物剂型:

TABLET (ENTERIC-COATED)

组成:

ACETYLSALICYLIC ACID 81MG

给药途径:

ORAL

每包单位数:

1000

处方类型:

OTC

治疗领域:

SALICYLATES

產品總結:

Active ingredient group (AIG) number: 0101169013; AHFS:

授权状态:

APPROVED

授权日期:

2014-07-30

产品特点

Jamp - ASA 81 mg EC Page 1 of 46
PRODUCT MONOGRAPH
JAMP - ASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg,
MB
Canada R2J 3W2
Control Number: 264031
Date of Preparation:
February 3, 2011
Date of Revision :
September 1, 2022
Jamp - ASA 81 mg EC Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
7
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE.....................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
....................................................................11
STORAGE AND STABILITY
...............................................................................................13
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................13
PART II: SCIENTIFIC INFORMATION
.........................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................14
CLINICAL
TRIALS................................................................